Compositions and methods related to site-specific identification of rna modifications
OwnerChuan He, Ralph R. Weichselbaum +2inventors
InventorsChuan He, Ralph R. Weichselbaum, Dali Han, Meng Xu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods related to cancer immunotherapy. In particular, the present disclosure identifies YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) as a novel therapeutic target for cancer immunotherapy. Embodiments of the present disclosure provide methods of enhancing cancer immunotherapy that involve attenuating YTHDF1 activity in various cells of the immune system (e.g., APCs) to induce a sufficient and lasting antitumor immune response.
Claims18
A method for enhancing cancer immunotherapy treatment comprising attenuating activity of YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) in a subject receiving treatment with an anticancer agent.
A composition for treating cancer comprising:
- an anticancer agent;
- and
- a YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) inhibitor.
A method for enhancing cancer immunotherapy treatment comprising attenuating activity of one or more lysosomal cathepsins in a subject receiving treatment with an anticancer agent.
Dependencies are inferred from the claim text.